How India Exports Torsemide to the World

Torsemide, a loop diuretic, has been approved in the United States through multiple Abbreviated New Drug Applications (ANDAs). According to the FDA's Orange Book, as of March 2026, there are 15 approved ANDAs for torsemide tablets, with the most recent approval granted in December 2025. This indicates a competitive generic market, facilitating access to this medication.

The United States is the primary destination for torsemide exports from India, accounting for 76.6% of the total export value between 2022 and 2026. This substantial market share underscores the importance of compliance with FDA regulations for Indian exporters. Notably, HETERO LABS LIMITED leads with a 58.0% share of these exports, highlighting its significant role in supplying torsemide to the U.S. market.

In the European Union, torsemide is subject to marketing authorization by the European Medicines Agency (EMA). As of March 2026, torsemide has been approved for use in several EU member states, adhering to the EU's Good Manufacturing Practice (GMP) requirements. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of torsemide, ensuring compliance with national standards.

Torsemide is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion signifies its recognized importance in treating priority health conditions globally. Additionally, torsemide formulations are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different regions.

In India, torsemide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for torsemide tablets, with the latest revision in January 2026, to ensure affordability. For export purposes, Indian manufacturers are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patents for torsemide have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has contributed to the widespread availability and affordability of torsemide globally.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List, reaffirming torsemide's inclusion due to its efficacy and safety profile. In August 2025, the NPPA revised the ceiling price for torsemide tablets, reflecting changes in production costs and market dynamics. In December 2025, the FDA approved a new ANDA for torsemide tablets, further increasing the number of generic options available in the U.S. market. In January 2026, the EMA issued updated guidelines on the manufacturing of loop diuretics, including torsemide, emphasizing stringent quality control measures. In February 2026, the MHRA conducted a review of torsemide's safety profile, concluding that the benefit-risk balance remains favorable for its approved indications.

India's pharmaceutical industry, including the production of Torsemide, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's APIs and KSMs are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to vulnerabilities, particularly when disruptions occur in China due to environmental regulations, trade policies, or other factors.

For instance, in June 2024, several Chinese chemical manufacturing plants faced shutdowns due to stringent environmental inspections, leading to a shortage of essential KSMs. This disruption had a cascading effect on Indian API manufacturers, resulting in increased production costs and potential delays in pharmaceutical outputs. Such incidents highlight the risks associated with over-dependence on a single country for critical raw materials.

Our proprietary trade data indicates a high supplier concentration in the export of Torsemide from India. The top five exporters account for 91.9% of the total export value, with HETERO LABS LIMITED alone contributing 58.0%. This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could disrupt the entire supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics, marking a step towards reducing import dependence. However, the effectiveness of these initiatives in diversifying the supplier base for Torsemide remains to be seen.

Recent geopolitical tensions have further exacerbated supply chain vulnerabilities. In March 2026, the conflict in Iran led to the effective closure of the Strait of Hormuz, a critical chokepoint through which approximately 20% of global oil passes. This disruption has not only affected energy supplies but also impeded the transportation of pharmaceuticals and raw materials, leading to increased shipping costs and potential delays.

Additionally, instability in the Red Sea and the Suez Canal, due to attacks by Houthi forces, has forced shipping companies to reroute vessels around the Cape of Good Hope. This detour adds approximately 10 to 14 days to transit times, further straining the pharmaceutical supply chain. While the FDA actively monitors such disruptions to prevent and mitigate shortages, the compounded effects of these geopolitical events pose a significant risk to the timely availability of Torsemide.

• Diversify Supplier Base: Encourage the development of alternative suppliers for APIs and KSMs, both domestically and in other countries, to reduce dependency on a single source.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to bolster local manufacturing capabilities for critical pharmaceutical ingredients.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and shipping routes, enabling proactive responses to potential disruptions.

• Develop Strategic Reserves: Establish reserves of essential APIs and KSMs to buffer against short-term supply interruptions.

• Foster International Collaboration: Engage in partnerships with other countries to create a more resilient and diversified global pharmaceutical supply chain.

RISK_LEVEL: HIGH